National Heart, Lung, and Blood Institute; Notice of Closed Meeting, 24846 [2024-07499]

Download as PDF 24846 Federal Register / Vol. 89, No. 69 / Tuesday, April 9, 2024 / Notices TABLE 1—NOTICES OF UPDATES TO RECOGNIZED OR UPDATED SUSCEPTIBILITY TEST INTERPRETIVE CRITERIA (STIC) BY DRUG 1—Continued Drug Route of administration Action taken Therapeutic category Date Piperacillin and Tazobactam. Injection ........................ Antibacterial ................. 1/17/2023 Plazomicin ..................... Injection ........................ Antibacterial ................. 4/21/2023 Polymyxin B .................. Injection ........................ Antibacterial ................. 1/17/2023 Rezafungin .................... Injection ........................ Antifungal ..................... 4/18/2023 Sulbactam and Durlobactam. Injection ........................ Antibacterial ................. 5/25/2023 Tobramycin .................... Injection ........................ FDA has updated STIC (MIC and disk diffusion) for Enterobacterales. FDA has recognized M100 standard for susceptible and resistant breakpoints and updated an intermediate breakpoint. FDA does not recognize M100 standard for a susceptible dose dependent breakpoint. (Rationale available at https:// www.fda.gov/drugs/development-resources/ fda-rationale-piperacillin-tazobactambreakpoints-enterobacterales.). FDA recognizes M100 standard (MIC and disk diffusion) for Enterobacterales. FDA does not recognize M100 standard (MIC) for Enterobacterales, Pseudomonas aeruginosa, or Acinetobacter spp. (Rationale available at https://www.fda.gov/drugs/development-resources/fda-rationale-polymyxinbreakpoints-enterobacterales-pseudomonasaeruginosa-and-acinetobacter-spp.). FDA identified STIC (MIC and disk diffusion) for C. albicans, C. glabrata, and C. tropicalis. FDA has reviewed STIC (MIC) for C. parapsilosis, and the M27M44S standard is recognized. FDA identified STIC (disk diffusion) for C. parapsilosis. FDA identified STIC (MIC and disk diffusion) for Acinetobacter baumannii-calcoaceticus complex. FDA does not recognize M100 standard (MIC and disk diffusion) for Enterobacterales and Pseudomonas aeruginosa. Antibacterial ................. 4/21/2023 1 M100 standard in the table refers to Clinical and Laboratory Standards Institute (CLSI) Performance Standards for Antimicrobial Susceptibility Testing, 33rd ed. CLSI supplement M100; 2023. Dated: April 4, 2024. Lauren K. Roth, Associate Commissioner for Policy. would constitute a clearly unwarranted invasion of personal privacy. [FR Doc. 2024–07495 Filed 4–8–24; 8:45 am] BILLING CODE 4164–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health ddrumheller on DSK120RN23PROD with NOTICES1 National Heart, Lung, and Blood Institute; Notice of Closed Meeting Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended. The contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the contract proposals, the disclosure of which VerDate Sep<11>2014 19:57 Apr 08, 2024 Jkt 262001 Name of Committee: National Heart, Lung, and Blood Institute Special Emphasis Panel; Hispanic Community Health Study—Study of Latinos (HCHS–SOL) Coordinating Center. Date: April 30, 2024. Time: 11:00 a.m. to 5:00 p.m. Agenda: To review and evaluate contract proposals. Place: National Institutes of Health, Rockledge I, 6705 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting). Contact Person: Susan Wohler Sunnarborg, Ph.D., Scientific Review Officer, Office of Scientific Review/DERA National, Heart, Lung, and Blood Institute, National Institutes of Health, 6705 Rockledge Drive, Room 208– Z, Bethesda, MD 20892, (301) 827–7987, susan.sunnarborg@nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.233, National Center for Sleep Disorders Research; 93.837, Heart and Vascular Diseases Research; 93.838, Lung Diseases Research; 93.839, Blood Diseases and Resources Research, National Institutes of Health, HHS) PO 00000 Frm 00071 Fmt 4703 Sfmt 4703 Dated: April 4, 2024. Melanie J. Pantoja, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2024–07499 Filed 4–8–24; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute on Alcohol Abuse and Alcoholism; Notice of Meeting Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of a meeting of the National Advisory Council on Alcohol Abuse and Alcoholism. This will be a hybrid meeting held inperson and virtually and will be open to the public as indicated below. Individuals who plan to attend inperson or view the virtual meeting and need special assistance or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting. The meeting E:\FR\FM\09APN1.SGM 09APN1

Agencies

[Federal Register Volume 89, Number 69 (Tuesday, April 9, 2024)]
[Notices]
[Page 24846]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-07499]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Heart, Lung, and Blood Institute; Notice of Closed 
Meeting

    Pursuant to section 1009 of the Federal Advisory Committee Act, as 
amended, notice is hereby given of the following meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 
U.S.C., as amended. The contract proposals and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the contract proposals, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Heart, Lung, and Blood Institute 
Special Emphasis Panel; Hispanic Community Health Study--Study of 
Latinos (HCHS-SOL) Coordinating Center.
    Date: April 30, 2024.
    Time: 11:00 a.m. to 5:00 p.m.
    Agenda: To review and evaluate contract proposals.
    Place: National Institutes of Health, Rockledge I, 6705 
Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).
    Contact Person: Susan Wohler Sunnarborg, Ph.D., Scientific 
Review Officer, Office of Scientific Review/DERA National, Heart, 
Lung, and Blood Institute, National Institutes of Health, 6705 
Rockledge Drive, Room 208-Z, Bethesda, MD 20892, (301) 827-7987, 
[email protected].

(Catalogue of Federal Domestic Assistance Program Nos. 93.233, 
National Center for Sleep Disorders Research; 93.837, Heart and 
Vascular Diseases Research; 93.838, Lung Diseases Research; 93.839, 
Blood Diseases and Resources Research, National Institutes of 
Health, HHS)

    Dated: April 4, 2024.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2024-07499 Filed 4-8-24; 8:45 am]
BILLING CODE 4140-01-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.